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        Appropriate immune responses to particular path-
ogens are orchestrated by distinct T cell popula-
tions with relatively stable cytokine expression 
profi  les that diff  erentiate during antigen-specifi  c 
clonal proliferation. Such diff  erentiation of CD4  +   
T cells is determined by signals provided by com-
ponents of the innate immune system and is sub-
sequently stabilized by induction and repression 
of key transcriptional regulators (  1  ). Recently, 
IL-17  –  producing CD4  +   T cells (Th17) have 
been identifi  ed as the key mediators of infl  amma-
tion and tissue damage in several animal models 
of human diseases (for review see references   1   
and   2  ). The commitment of naive murine CD4  +   
T cells to the Th17 lineage requires exposure to 
TGF-     and either IL-6 (  1, 3, 4  ) or IL-21 (  2, 5, 
6  ). These cytokines act in a STAT3-dependent 
manner to induce expression of retinoid-related 
orphan receptor     t (ROR    t), the critical tran-
scription factor necessary for the development of 
Th17 cells (  7  –  10  ), which subsequently induces a 
set of eff  ector molecules, including IL-17, IL-21, 
IL-22, and IL-23R plus several chemokines and 
other defense molecules (  1, 2  ). In contrast to 
mice, much less is known about the requirements 
for generating human Th17 cells. Indeed, al-
though there is consensus that TGF-     is not re-
quired for this process, and is actually inhibitory, 
controversy exists as to whether IL-6 or IL-23, in 
combination with IL-1    , is the predominant cue 
that mediates commitment of human naive CD4  +   
T cells to the Th17 lineage (  11, 12  ). Given these 
diff  erences, it is important to dissect further the 
molecular requirements for the development of 
human Th17 cells. 
  Although inappropriate Th17 diff  erentiation 
helps explain autoimmune disease and infl  am-
mation, the physiological function of Th17 cells 
appears to lie in host protection against specifi  c 
pathogens (  1, 2  ). Based on the anatomical distri-
bution of Th17 cells and the capacity of IL-17 to 
regulate granulopoiesis, neutrophil chemotaxis, 
and production of microbiocidal peptides by 
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  Hyper  –  immunoglobulin E syndrome (HIES) is a primary immune defi  ciency characterized by 
abnormal and devastating susceptibility to a narrow spectrum of infections, most commonly 
  Staphylococcus aureus   and   Candida albicans  . Recent investigations have identifi  ed muta-
tions in   STAT3   in the majority of HIES patients studied. Despite the identifi  cation of the 
genetic cause of HIES, the mechanisms underlying the pathological features of this disease 
remain to be elucidated. Here, we demonstrate a failure of CD4  +   T cells harboring heterozy-
gous   STAT3   mutations to generate interleukin 17  –  secreting (i.e., T helper [Th]17) cells in 
vivo and in vitro due to a failure to express suffi  cient levels of the Th17-specifi  c transcrip-
tional regulator retinoid-related orphan receptor     t. Because Th17 cells are enriched for 
cells with specifi  cities against fungal antigens, our results may explain the pattern of 
infection susceptibility characteristic of patients with HIES. Furthermore, they underscore 
the importance of Th17 responses in normal host defense against the common pathogens 
  S. aureus   and   C. albicans  . 1552 TH17 DEFICIENCY IN HYPER IGE SYNDROME   | Ma et al. 
    RESULTS AND DISCUSSION   
  Characteristics of HIES patients and   STAT3   mutations 
  Five unrelated patients with HIES were identifi  ed according 
to their clinical phenotype (  Table I  ).   One patient (HIES4) 
had a family history of HIES (her mother had succumbed to 
infection but was not available for this analysis). All patients 
had a history of recurrent infection, including invasive   S. aureus   
and mucocutaneous candidiasis. In addition, all patients had 
features typical of the autosomal-dominant form of HIES, with 
abnormalities of the skeleton, teeth, and soft tissue (  Table I  ). 
Phenotype scores ranged from 26 to 71 according to the pro-
posed HIES score (an age-sensitive scoring with HIES being 
most likely in patients with a score   >  40) (  21  ). 
  Genomic DNA was isolated from each patient, and exons 
13  –  21 of   STAT3  , which encompass the DNA binding and 
SH2 domains, were sequenced. Heterozygous missense mu-
tations were identifi  ed in all fi  ve patients. Four harbored mu-
tations in the DNA binding domain (R382Q [ n   = 2], V432M, 
and H437P) and one had a mutation in the SH2 domain 
(Q644P;   Table I  ). The R382 residue is a common site of 
mutation, accounting for     30% (18/58) of reported HIES 
genotypes, with R382Q in 8 of those 18 (  19, 20  ). Most 
of the mutations we identifi  ed have previously been dem-
onstrated to impair the ability of STAT3 to translocate to 
the nucleus and activate transcription of STAT3 target genes 
(  19, 20, 22  ). 
  Heterozygous   STAT3   mutations abrogate the generation 
of Th17 cells in vivo 
  To test the hypothesis that missense mutations in   STAT3   
would confer a defect in human Th17 cell diff  erentiation, 
CD4  +   T cells from HIES patients were examined and com-
pared with those from matched normal controls. Flow cyto-
metric analysis revealed normal development of CD4  +   T cells, 
epithelium in mice, it is likely that Th17 cells confer immunity 
to pathogens on mucosal and possibly other epithelial surfaces 
(  8, 13  ). For instance, Th17 cells appear to have a predominant 
role in antifungal immune responses in both humans and 
mice (  14  –  16  ). 
  Hyper-IgE (HIES), or Job  ’  s, syndrome (OMIM 147060) 
is a primary immune defi  ciency characterized by abnormal 
susceptibility to a narrow spectrum of infections, most com-
monly   Staphylococcus aureus   and   Candida albicans   (  17, 18  ). Pa-
tients with HIES often suff  er from mucocutaneous candidiasis, 
whereas local and invasive   S. aureus   infections lead to persis-
tent eczematoid eruptions, recurrent skin and joint abscesses, 
and lung damage. In addition to recurrent tissue-destructive 
infections, the HIES phenotype includes coarse facies, osteo-
penia resulting in fractures after relatively minor trauma, sco-
liosis and craniosynostosis, delayed shedding of the primary 
dentition, and short stature (  18  ). Patients also exhibit dra-
matic increases in serum IgE (  >  10 times normal) (  17, 18  ). 
Recently, heterozygous missense mutations and short dele-
tions in   STAT3   have been identifi  ed in the majority of HIES 
patients studied (  19, 20  ). Despite the identifi  cation of the 
  genetic cause of HIES, the mechanisms underlying the path-
ological features of this disease remain to be elucidated. Based 
on the observations that (a) defects in immunity to both   
Candida   and   S. aureus   are prominent features of HIES, espe-
cially at epithelial surfaces (  18  ), (b) human Th17 cells have 
specifi  cities for fungal antigens, including   C. albicans   (  14  ), (c) 
heterozygous   STAT3   mutations are responsible for HIES 
in the majority of cases (  19, 20  ), and (d) the development of 
murine Th17 cells is compromised in mice lacking expression 
of STAT3 in their CD4  +   T cells (  7, 9, 10  ), we hypothe-
sized that   STAT3   mutations conferred specifi  c susceptibility 
in humans with HIES to infection via an inability to generate 
Th17 cells. 
  Table I.      Characteristics of HIES patients 
  HIES 1    HIES 2    HIES 3    HIES 4    HIES 5 
Age 18 18 15 7 42
Sex M M M F F
Infection
Candidiasis Yes No Yes Yes Yes
  S. aureus   pneumonia Yes Yes No No Yes
  S. aureus   abscesses Yes Yes Yes Yes Yes
Other serious infection No No No No No
Parenchymal lung damage Yes Yes No No Yes
Characteristic face Yes Yes Yes Yes Yes
Retained primary teeth Yes Yes Yes   — Yes
Fractures Yes Yes Yes No No
Phenotype score (  21  ) 7 15 05 42 66 3
IgE (kIU/L) 18,314 37,620 2,545 8,075 7,491
Genotype V432M R382Q R382Q H437P Q644P
Affected STAT3 domain DNABD DNABD DNABD DNABD SH2
DNABD, DNA binding domain; SH2, src homology 2 domain.JEM VOL. 205, July 7, 2008  1553
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cells could be detected after stimulation of CD4  +   T cells from 
two HIES patients (  Fig. 1, B and C  ). These fi  ndings were 
corroborated by examination of IL-17 secretion by stimu-
lated CD4  +   T cells. Control CD4  +   T cells secreted abundant 
quantities of IL-17, whereas IL-17 was undetectable in cul-
tures of CD4  +   T cells from four of fi  ve HIES patients (  Fig. 
1 D  ). In the fi  fth patient, the concentration of IL-17 was 
  >  20-fold lower than the average amount produced by con-
trol CD4  +   T cells (  Fig. 1 D  ). 
  To exclude a diff  erence in the rate of IL-17 secretion by 
HIES CD4  +   T cells, production of IL-17 by activated CD4  +   
T cells from healthy donors and HIES patients was measured 
over an 11-d time course. In cultures of healthy CD4  +   T 
cells, IL-17 was fi  rst detected after 4 d, peaked on days 5  –  6, 
and remained stable or declined at later times (  Fig. 1 E  ). In 
contrast, no IL-17 was detected in the supernatants of HIES 
CD4  +   T cells at any of the time points examined (  Fig. 1 E  ). 
We also assessed expression of IL-22, a Th17-derived cyto-
kine thought to be important in epithelial immunity (  23, 24  ). 
IL-22 mRNA (  Fig. 1 F  ) was signifi  cantly reduced in acti-
vated CD4  +   T cells from HIES patients compared with 
healthy controls (P   <   0.01). Furthermore, there was a com-
plete absence of IL-22 secretion in cultures of activated CD4  +   
T cells (  Fig. 1 G  ). This fi  nding demonstrates that production 
of both IL-17 and IL-22 by in vivo  –  generated Th17 cells is 
dependent on functional STAT3 protein and confi  rm that 
IL-22 is a signature Th17 cytokine. 
  HIES CD4  +   T cells fail to up-regulate expression of ROR    t, 
the Th17 lineage  –  specifi  c transcriptional regulator 
  Diff  erentiation of Th17 cells is determined by ROR    t (  8  ). 
Because induction of this key transcription factor in mice is 
regulated by STAT3 (  7, 9, 10  ), we tested for a possible defect 
in the expression of ROR    t mRNA in HIES CD4  +   T cells. 
We found a fourfold reduction of ROR    t message in stimu-
lated HIES CD4  +   T cells compared with control CD4  +   T 
cells (  Fig. 2 A  ).   
  Given that STAT3 monomers must undergo homodimer-
ization to be functional (  25  ), a fourfold reduction in expression 
of ROR    t is consistent with the prediction that a single mutant 
allele of   STAT3   would reduce functional STAT3 homodimers 
with comparable proportions of naive (CD45RA  +   CD27  +  ), 
central memory (CD45RA        CD27  +  ) and eff  ector memory 
(CD45RA        CD27       ) cells in HIES patients and healthy con-
trols (not depicted). 
  To investigate whether Th17 cells were present within 
the circulating T cell population of HIES patients in vivo, 
total CD4  +   T cells were stimulated in vitro with anti-CD3 
mAb, anti-CD28 mAb, and IL-2 for 4  –  5 d. The proportion 
of Th17 cells within the population was assessed by intracel-
lular staining for IL-17 after restimulation with PMA and 
ionomycin. A small but consistent population of IL-17  –  ex-
pressing cells was detected in the CD4  +   T cells examined for 
all healthy donors (1.2%;   n   = 5;   Fig. 1, A and C  ).   In contrast, 
there was a signifi  cant reduction in IL-17  +   cells from the 
  cultures of stimulated   STAT3   mutant HIES CD4  +   T cells 
(0.44%;   n   = 5; P   <   0.05;   Fig. 1, B and C  ). Indeed, no IL-17  +   
    Figure 1.         HIES patients have a defect in the generation of IL-17  –
  producing CD4  +   T cells in vivo.   Intracellular expression of IL-17A and 
IL-2 in purifi  ed CD4  +   T cells from a healthy donor (A) and a HIES patient 
(B) activated for 5 d (see Materials and methods). (C) The frequency of IL-
17A  +   cells, determined by intracellular cytokine expression, and (D) IL-17A 
secretion by CD4  +   T cells from fi  ve healthy donors and fi  ve HIES patients 
that had been stimulated with anti-CD3 mAb, anti-CD28 mAb, and IL-2 
for 4  –  5 d, as determined by ELISA. Each symbol represents the value from 
an individual donor or patient, and the line represents the mean. (E) Time 
course of IL-17A secretion by CD4  +   T cells isolated from a normal donor 
and HIES patient. Similar results were obtained when CD4  +   T cells from all 
HIES patients were examined over a culture period that continued for up 
to 11 d. (F and G) Expression of IL-22 mRNA (relative to housekeeping 
genes; F) and secreted protein (G) by normal and HIES CD4  +   T cells was 
determined after 2 and 5 d, respectively, of stimulation with CD3/CD28/
IL-2. *, P   <   0.05; **, P   <   0.01.     
    Figure 2.         Defi  ciency of ROR    t mRNA in HIES patients  . (A) ROR   t 
mRNA expression in CD4  +   cells activated for 2 d with CD3/CD28/IL-2 in 
fi  ve HIES patients and fi  ve normal controls. (B) ROR    t mRNA expression 
after 2 d of culture is proportional to the number of Th17 cells as deter-
mined by intracellular cytokine expression after 4  –  5 d.     1554 TH17 DEFICIENCY IN HYPER IGE SYNDROME   | Ma et al. 
by 75%. In our cohort of patients, the quantity of ROR    t 
mRNA correlated with the number of Th17 cells induced after 
stimulation in vitro  ,   which would be expected if ROR    t spec-
ifi  es Th17 diff  erentiation (  Fig. 2 B  ). 
  HIES CD4  +   T cells can proliferate, produce Th1- 
and Th2-type cytokines, and undergo in vivo 
differentiation to T regulatory (T reg) and T follicular 
helper (T  FH  ) cell phenotypes 
  The defect in IL-17 secretion and Th17 cell diff  erentiation by 
HIES CD4  +   T cells did not appear to result from a general defect 
in lymphocyte activation. HIES CD4  +   T cells proliferated to a 
similar extent as control counterparts (  Fig. 3 A  ).   Furthermore, 
there was no signifi  cant defect in production of IFN-     (  Fig. 3, 
B  –  E  ), TNF-     (  Fig. 3 F  ), IL-4, or IL-13 (  Fig. 3, G and I  ). IFN-     
secretion by activated HIES CD4  +   T cells was reduced com-
pared with controls (  Fig. 3 E  ), but this reduction did not reach 
statistical signifi  cance, and there was no defi  ciency of IFN-      –
  producing cells when assessed by fl  ow cytometry after restimula-
tion with PMA/ionomycin. Interestingly, there was a consistent 
and signifi  cant reduction (    3.5-fold; P   <   0.01) in IL-10 pro-
duction by CD4  +   T cells from all HIES patients examined rela-
tive to production by control CD4  +   T cells (  Fig. 3 H  ). This 
probably refl  ects a specifi  c intrinsic requirement for STAT3 in 
IL-10 production by activated CD4  +   T cells, as recently demon-
strated in mice that specifi  cally lack STAT3 in their CD4  +   T 
cells (  26  ). Despite reductions in secretion of IFN-     and IL-10, 
measurable amounts of these cytokines were clearly present 
in the cultures of activated CD4  +   T cells from HIES patients 
(  Fig. 3 I  ), which contrasts the complete defi  cit in IL-17 produc-
tion by these cells (  Fig. 1, D and E  ). Interestingly, HIES CD4  +   
T cells consistently gave rise to an increased frequency of cells 
expressing IL-2 compared with normal controls (  Fig. 3, B  –  D  ). 
Furthermore, T reg cells (defi  ned as CD4  +  CD25  hi  CD127  lo   cells) 
(  27  ) and T  FH   cells (defi  ned as CD4  +  CXCR5  +   cells) (  28  ) were 
found to be present in normal numbers ex vivo in HIES patients 
(  Fig. 3, J and K  ). 
  It has been recently reported that Th17 cells express the 
chemokine receptor CCR6 (  14, 29  ). Because IL-17  –  produc-
ing cells were absent from the CD4  +   T cell compartment of 
HIES patients, we enumerated CD4  +   CCR6  +   T cells in pe-
ripheral blood. In healthy donors,     20% of CD4  +   T cells ex-
pressed CCR6 (  Fig. 3 L  ). In contrast,   <  10% of CD4  +   T cells 
expressed CCR6 in HIES patients (  Fig. 3 L  ), consistent with 
the suggestion that CCR6 identifi  es Th17 cells. Further-
more, because human CCR6  +   CD4  +   T cells have been 
shown to secrete both IL-17 and IFN-     under some circum-
stances (  29  ), defi  ciency of this subset might account for the 
reduction in IFN-     sometimes observed in HIES. It is im-
portant to emphasize that previous assessments of IFN-     pro-
duction in HIES are inconsistent, which could also be due to 
heterogeneity of HIES cohorts before genotyping for   STAT3   
    Figure 3.         CD4  +   T cells from HIES patients undergo normal prolif-
eration and differentiation into Th1-, Th2-, T reg  –  , and T  FH  -type 
effector cells.   (A) CFSE profi  les of normal (outline black histogram) and 
HIES (solid red histogram) CD4  +   T cells after stimulation with CD3/CD28 
mAb and IL-2 for 5 d. (B) Intracellular expression of IFN-     and IL-2 in 
CD4  +   T cells purifi  ed from normal donors and HIES patients after activa-
tion for 4  –  5 d with CD3/CD28/IL-2. The FACS plots in B are representative 
of one normal control and one HIES patient. (C and D) Frequency of CD4  +  
T cells from normal controls and HIES patients that expressed IL-2 (C) or 
IFN-     (D). (E  –  I) Secretion of IFN-     (E),  TNF-    (F), IL-4 (G), IL-10 (H), and 
IL-13 (I) by normal and HIES CD4  +   T cells stimulated with anti-CD3/CD28 
mAb and IL-2 for 5 d. (J and K) CD4  +   T cells were labeled with either (J) 
CD25 and CD127 to identify T reg cells (CD25  hi CD127 lo  ) or (K) CXCR5 to 
identify T  FH   cells, as indicated by the gated populations. The values repre-
sent the frequency of gated cells and are from one healthy donor and one 
HIES patient and are representative of at least four patient and control 
samples. (L) PBMCs were labeled with anti-CD4 and CCR6 mAb, and the 
frequency of CD4  +   CCR6 +   cells in healthy donors and HIES patients was 
enumerated. For all graphs (E  –  I and L), each symbol represents the value 
from an individual donor or patient, and the line represents the mean. 
*, P   <   0.05; **, P   <   0.01; ns, not signifi   cant.   
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and IL-23 (  31  ) to both activate STAT3. Furthermore, al-
though IL-23 can also activate STAT-1, -4, and -5 (  31  ), it 
would appear that IL-23  –  induced activation of STAT3 plays 
a predominant role in amplifying the generation of Th17 cells 
from human naive CD4  +   T cells induced by IL-6 (  Fig. 2  ). 
  Our fi  ndings identify a fundamental defect in Th17 diff  er-
entiation in HIES. Thus, enumeration of IL-17 production by 
activated CD4  +   T cells, coupled with measuring the frequency 
of CCR6  +  CD4  +   T cells, emerges as a relatively quick and sim-
ple procedure that could be used to screen patients suspected of 
having HIES due to inactivating mutations in   STAT3  . In ad-
dition, our fi  ndings also point to a crucial role for Th17 cells in 
the normal host response. Infections with   Candida   spp. and 
  S. aureus  , the most prevalent etiological agents in the infections 
encountered in patients with HIES, are also important patho-
gens in other clinical settings. Mechanisms for defense against 
  Candida   and other fungal infections have been contentious. Al-
though human Th17 cells respond selectively to   Candida   (  14  ), 
other evidence suggests that production of IL-17 and IL-23 in-
creases susceptibility to fungal infection in vivo (  32  ). Further-
more, a role for T reg cells has been proposed, whereby 
down-regulation of Th17-mediated infl  ammation is necessary 
to prevent fungal-induced pathology (  33  ). However, we did not 
detect a defi  ciency of T reg cells, at least by cell surface pheno-
type, in HIES. Our observations using CD4  +   T cells from 
HIES patients supports the data of Acosta-Rodriguez et al. (  14  ) 
that Th17 cells play a crucial role in coordinating the host 
defense against   Candida  . This most likely refl  ects a direct func-
tion of IL-17 produced by Th17 cells, as demonstrated by the 
requirement of the IL-17R in protective immune responses in 
mice to infection with   C  .   albicans   (  15  ). Recent evidence from 
Milner et al. (  30  ) demonstrates that CD4  +   T cells from HIES 
patients fail to diff  erentiate in vitro into IL-17  –  producing 
became available. Indeed, recent evidence indicates that some 
HIES-like patients with normal STAT3 exhibit defi  ciencies 
of IFN-     production, whereas STAT3-defi  cient patients 
have no IFN-     defect (  30  ). 
  Naive CD4  +   T cells fail to differentiate into Th17 cells 
in vitro 
  Human naive CD4  +   T cells do not produce IL-17 when stimu-
lated through CD3 and CD28 (  11, 12  ). Thus, the detection of 
IL-17 in the cultures of total CD4  +   T cells activated with anti-
CD3/CD28 mAb refl  ects production by memory CD4  +   T cells 
that have diff  erentiated to the Th17 lineage in vivo. The re-
quirement of STAT3 in CD4  +   T cell diff  erentiation in vivo ap-
pears to be specifi  c to the Th17 lineage because CD4  +   T cells 
from HIES patients could give rise to eff  ector cells with features 
of Th1-, Th2-, T reg  –  , and T  FH  -type cells in vivo. Because 
STAT3 is ubiquitously expressed and functions downstream of 
numerous cytokine receptors (  25  ), it was possible that the in-
ability to generate Th17 cells in vivo was a consequence of a re-
quirement for STAT3 function in non-CD4  +   T cells, for 
instance antigen-presenting cells, that instruct the diff  erentiation 
of CD4  +   T cells. It was therefore important to demonstrate an 
intrinsic requirement of STAT3 in naive CD4  +   T cells for their 
commitment to the Th17 lineage. Thus, naive CD4  +   T cells 
were sort-purifi  ed and then cultured with beads coated with anti-
CD2, anti-CD3, and anti-CD28 together with various com-
binations of IL-1    , IL-6, and IL-23. Secretion of IL-17A by 
normal CD4  +   T cells was not detected until the cells had been 
subjected to three rounds of stimulation in vitro with anti-CD2, 
anti-CD3 plus anti-CD28 mAb-coated beads, and either IL-1     
plus IL-6 or IL-23, with each stimulation period lasting 4  –  5 d 
(  Fig. 4 A  ).   The combination of IL-1     plus IL-6 was approx-
imately fi  vefold more eff  ective at inducing production of IL-
17A by activated naive CD4  +   T cells than IL-23, and there was 
a further two- to threefold increase in the presence of all three 
cytokines (  Fig. 4 A  ). In complete contrast, when naive HIES 
CD4  +   T cells were cultured under the same optimized condi-
tions they failed to produce IL-17A (  Fig. 4 A  ). Although these 
culture conditions induced IL-17A, we were unable to detect 
IL-17A  –  expressing cells by intracellular staining (not depicted). 
Because only     1% of total activated CD4  +   T cells expressed IL-
17A, yet secreted up to 10,000 pg/ml IL-17A (see   Fig. 1, A  –  E  ), 
our inability to detect IL-17A  +   cells in cultures of naive CD4  +   T 
cells most likely refl  ects the fact that these cells secreted 10  –  20-
fold less IL-17A than memory CD4  +   T cells. 
  Consistent with the defect in diff  erentiation of naive HIES 
CD4  +   T cells into Th17 cells in the presence of IL-1    , IL-6, 
and IL-23, we demonstrated a defect in induction of ROR    t 
in T cells in response to each of these stimuli. The induction 
of ROR    t mRNA was   >  10-fold greater in IL-23  –  containing 
culture conditions in normal CD4  +   T cells compared with 
those from HIES patients (  Fig. 4 B  ). Interestingly, induction 
of ROR    t expression appeared to be absolutely dependent 
on IL-23, whereas there was a lesser eff  ect of IL-6 (  Fig. 4 B  ). 
These fi  ndings recapitulate the in vivo Th17 diff  erentiation 
defect in HIES and are consistent with the ability of IL-6 (  25  ) 
    Figure 4.         Naive CD4  +   T cells from HIES patients fail to differenti-
ate to the Th17 lineage in vitro in response to the STAT3-activating 
cytokines IL-6 and IL-23.   Naive  CD4 +   T cells isolated from a normal 
donor (   ,     ) and a HIES patient (   ,     ) were cultured with anti-CD2, 
anti-CD3, and anti-CD28 mAb-coated beads either alone (CD3) or in the 
presence of IL-1     plus IL-6 (IL-1    +IL-6), IL-23 (IL-23), or all three cyto-
kines (IL-1     +IL-6+IL-23). The cells were harvested after 5 d and then 
recultured under the same conditions for another two rounds of stimula-
tion. (A) IL-17A secretion was determined after either 3 d (   ,    ;  total 
time of culture, 12 d) or 6 d of the third round of restimulation (   ,    ; 
total time of culture, 15 d). (B) Expression of ROR    t mRNA in cells stimu-
lated for 5 d (   ,     ) or 15 d (   ,     ) was determined by quantitative PCR.     1556 TH17 DEFICIENCY IN HYPER IGE SYNDROME   | Ma et al. 
TCTGTCCAACCTACCCTTCG; exon 20, GGACAGAGTGTGCACA-
GATGTAA and CACTGGAGCAAGCAAAACAA; and exon 21, GCTTA-
AGTCTTTTCCCCTTCG and GCATTTGCCTATCTATCCTCCA. 
  CD4  +   T cell isolation, phenotyping, and cell culture.     Whole blood was 
collected from normal donors and HIES patients, and PBMCs were prepared 
by centrifugation using Ficoll-Paque. CD4  +   T cells were then isolated by 
positive selection using the CD4-DYNA beads. Purifi  ed CD4  +   T cells were 
cultured in 24-well plates (2   ×   10  5   cells/ml) with immobilized 5   μ  g/ml anti-
CD3 mAb, 750 ng/ml anti-CD28 mAb, and 20 U/ml rIL-2 (  37  ). CD4  +   T 
cells were also labeled with CFSE (  37  ), and their proliferation was determined 
after 5 d of in vitro culture. For in vitro diff  erentiation to the Th17 lineage, 
naive CD4  +   T cells were isolated by sorting CD45RA  +  CD27  +   cells (  37  ) and 
then culturing them with anti-CD2  –  , anti-CD3  –  , and anti-CD28  –  coated 
beads (one bead per fi  ve cells), and 20 U/ml rIL-2 alone or in the presence of 
20 ng/ml IL-23 only, 10 ng/ml IL-1     plus 50 ng/ml IL-6, or IL-1    , IL-6, 
and IL-23. The cells were harvested every 4  –  5 d before being washed and re-
cultured under the same conditions at 2   ×   10  5   cells/ml (  11, 12  ). 
  The frequencies of CD4  +   T cells that were of a naive, conventional 
memory, or eff  ector memory phenotype, were determined by enumerating 
CD4  +   T cells that were either CD45RA  +  CD27  +  , CD45RA       CD27  +  , or 
CD45RA       CD27       , respectively. T reg and T  FH   cells were quantitated by 
determining the frequency of CD4  +   T cells that had a CD25  hi  CD127  lo   (  27  ) 
or CXCR5  +   (  28  ) phenotype, respectively. 
  Intracellular cytokine staining and ELISA.     After 5 or 6 d of activation 
with the conditions mentioned above, CD4  +   T cells were harvested and re-
stimulated for 6 h with 100 ng/ml PMA and 750 ng/ml ionomycin, with 10 
  μ  g/ml brefeldin A added after 2 h. After this time, cells were fi  xed in 2% 
formaldehyde (Sigma-Aldrich) and stained for expression of intracellular cy-
tokines (IL-2, IL-17A, and IFN-    ). All antibody staining and wash steps 
were performed in 0.5% saponin solution (  37  ). Data were acquired using a 
FACSCanto or LSRII (BD Biosciences) and analyzed using FlowJo software 
(Tree Star). IL-17A in culture supernatants was measured using the human 
IL-17A ELISA Ready-SET-Go kit according to the manufacturer  ’  s instruc-
tions (eBioscience). IL-22 secretion was measured using the Human IL-22 
ELISA Development kit from PeproTech. Secretion of IL-4, IL-10, IL-13, 
IFN-    , and TNF-     was determined by ELISA using purifi  ed and biotinyl-
ated cytokine-specifi  c mAb (IL-4: 8D4-8 and MP4-25D2; IL-10: JES3-
12G8 and JES3-9D7; IL-13: PVM13-1 and polyclonal; IFN-    : NIB42 and 
4S.B3; TNF-    : MAb1 and MAb11; from BD Biosciences and eBioscience) 
as the capture and detection mAbs, respectively, and visualization with strep-
tavidin  –  horseradish peroxidase and TMB substrate. 
  mRNA quantitation.     After 2 d of culture, CD4  +   T cells were harvested and 
washed with PBS. Total RNA was isolated using the QIAGEN RNeasy kit 
according to the manufacturer  ’  s instructions. For quantitative RT-PCR, total 
RNA was reverse transcribed using oligo-dT according to the Invitrogen pro-
tocol. cDNA expression was determined using the ABI Prism 7900 sequence 
detection system and Syber-green reagents (Applied Biosystems). The fol-
lowing primers were used:   ROR    t  , TCAGTCATGAGAA  CACAAATTGA 
and GCACCCCTCACAGGTGATAA;   UBE2D2  , TGAAGAGAATCCA-
CAAGGAATTGA and CAACAGGACCTG  CTGAACACTG; and   IL22  , 
AGGCTCAGCAACAGGCTAAG and TCCTTCAGCTTTTGCACATT. 
Fluorescence signals were measured over 40 PCR cycles, and the cycle (Ct) 
at which signals crossed a threshold set within the logarithmic phase was re-
corded. The Ct for the target gene was subtracted from the Ct for UBE2D2 
(    Ct). The relative amount of mRNA was calculated as 2    Δ  Ct  . 
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eff  ector cells in response to stimulation with   C. albicans   and 
  S. aureus  . Defi  ciency of IL-17 is not necessarily the only mech-
anism of immunodefi  ciency in HIES because IL-22 has been 
shown to contribute to protection against   Klebsiella pneumoniae   
in mice (  23  ), and we show that IL-22 production is also re-
duced signifi  cantly in HIES. 
  Although our fi  ndings help to explain the spectrum of infec-
tions in HIES, other aspects of the complex phenotype require 
elucidation. A similar cell-intrinsic eff  ect of STAT3 acting within 
chondrocytes or osteoblasts may explain some of the skeletal 
defects as evidenced in mice with a conditional hematopoietic 
cell-specifi  c disruption of the STAT3 gene (  34  ). Craniosynosto-
sis and midline abnormalities, for example, can result from de-
fects in the transcription factor TWIST, which is induced by 
STAT3 (  35, 36  ). The mechanism of the HIES component of 
the phenotype is also likely to be complex because STAT3 op-
erates intrinsically in B cells and is activated in response to many 
regulatory cytokines, including IL-6, IL-10, and IL-21, and, as 
shown here, T helper signals are also disrupted. 
  Finally, illumination of the aspects of the HIES phenotype 
that arise as a consequence of Th17 defi  ciency may sound a 
note of caution when considering IL-17 antagonism in auto-
immune and infl  ammatory diseases (  9, 10  ). On the other hand, 
administration of IL-17 or IL-22 may represent a therapeutic 
approach to controlling specifi  c pathogen infections in HIES 
patients, as well as in other patient groups who exhibit suscep-
tibility to   Candida  . 
  MATERIALS AND METHODS 
  Reagents.     Allophycocyanin-conjugated anti  –  IFN-     mAb was purchased 
from Invitrogen, and FITC  –  anti  –  IL-17A was purchased from eBioscience. 
Alexa 647 –  anti-CXCR5, allophycocyanin –  anti-CD25, FITC –  anti-CD45RA, 
PE-conjugated anti  –  IL-2 and anti-CD27, PE-Cy7  –  anti-CD4, and PE  –  anti-
CCR6 were purchased from BD Biosciences. ECD-conjugated anti-CD4 and 
PE  –  anti-CD127 were from Beckman Coulter. Recombinant human IL-2 
(rIL-2) was purchased from Endogen, recombinant human IL-1     and IL-6 
were from PeproTech, and recombinant human IL-23 was purchased from 
eBioscience. Anti-CD28 mAb was purchased from BD Biosciences, anti-CD3 
mAb (Spv-T3b) was provided by H. Spits (NKI, Amsterdam, Netherlands), 
and anti-CD2  –  , anti-CD3  –  , and anti-CD28  –  coated beads were purchased 
from Miltenyi Biotec (T cell activation/expansion kit). PMA, calcium iono-
phore (ionomycin), brefeldin A, and saponin were all purchased from Sigma-
Aldrich. CFSE was purchased from Invitrogen. 
  Patients.     Five normal donors and fi  ve patients with the clinical diagnosis of 
HIES were recruited from Immunology Clinics in Canberra and Sydney, 
Australia. The cited HIES score (  21  ) is age sensitive; therefore, the low score 
in the 7-yr-old patient did not argue against testing her for mutations in 
  STAT3  . All studies were approved by the institutional human research ethics 
committees (Canberra and Westmead hospitals). 
  Identifi   cation of STAT3 mutations in HIES patients.     Genomic 
DNA was isolated from saliva samples, and exons 13  –  21 encompass-
ing the DNA binding and SH2 domains were amplifi  ed by PCR and se-
quenced (ABI Prism 7700). The following primers were used: exons 12  –  14, 
TAGTTTAAAGAAATGCCCAGGAGCACAGAG and TTGGCCTA-
AGTGACTTTTTGGAATAACTACAGC; exon 15, TGCTGTGCT-
GCTTAGACTGG and CCCCTGTACGTAGCCTCTCCA; exon 16, 
GAGATGCGGGTGAAGAGATT and CTTGTTTAGATGAGGGATG-
GTG; exon 17, AGTGCCCCCTCCTTTTAGTT and CCCAAATGAA-
CAGCCCTATG; exons 18 and 19, TGCACACACACAACAGTGC and JEM VOL. 205, July 7, 2008  1557
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